Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Shi, YK; Su, H; Song, YP; Jiang, WQ; Sun, XH; Qian, WB; Zhang, W; Gao, YH; Jin, ZM; Zhou, JF; Jin, C; Zou, LQ; Qiu, LG; Li, W; Yang, JM; Hou, M; Zeng, S; Zhang, QY; Hu, JD; Zhou, H; Xiong, Y; Liu, P

Shi, YK (reprint author), Peking Union Med Coll, Beijing 100021, Peoples R China.; Shi, YK (reprint author), Chinese Acad Med Sci, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing 10

LANCET HAEMATOLOGY, 2019; 6 (1): E12

Abstract

Background Sintilimab (Innovent Biologics, Suzhou, China), a highly selective, fully humanised, monoclonal antibody, blocks the interaction between PD......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索